initi coverag immunov imvt alpha seri descript
within page pdf outperform rate price target
immunov develop potenti best-in-class neonat fc receptor fcrn inhibitor
treatment igg driven autoimmun diseas fcrn key regul igg catabol
use led robust igg reduct human favor compar competitor
class note design onset subcutan sc administ
pk/pd mode deliveri look best-in-class time immunov current
conduct phase ii studi grave ophthalmopathi go myasthenia gravi mg warm
autoimmun hemolyt anemia waiha data readout expect earli base
convers fcrn diseas specif expert believ trial good chanc
success current model world-wide sale risk adjust
indic note fcrn inhibitor use rang addit igg-medi condit
expect class gener sever billion revenu let look
fcrn inhibitor significantli improv soc igg mediat autoimmun
diseas mani autoimmun diseas target therapi exist instead treatment
broadli suppress immun respons includ plasmapheresi iv immunoglobulin therapi
ivig corticosteroid rituximab still commonli use even though associ
consider limit advers event profil said american relat diseas
associ aarda estim us autoimmun market greater monoclon
antibodi inhibit fcrn prevent transport recycl igg back circul
significantli reduc antibodi half-lif therefor therapeut potenti
transform treatment autoimmun diseas mediat pathogen igg autoantibodi
fcrn inhibitor immunov competitor alreadi shown significantli reduc
igg concentr healthi volunt patient turn expect allevi
symptom multipl autoimmun diseas proof concept alreadi establish
variou diseas includ myasthenia gravi mg immun thrombocytopenia purpura itp
pemphigu vulgari pv ultim anti-fcrn class potenti offer patient
igg-medi autoimmun diseas efficaci conveni toler form diseas
manag compar current approach
 top-line result phase iia studi go
 top-line result phase iia studi mg
 top-line result phase iia studi waiha
earli top-line result random phase iib studi go
 begin pivot phase studi mg
year left
spac close decemb
analyst certif disclosur pleas see page
potenti best class anti-fcrn therapi fcrn inhibitor clinic develop includ
immunov efgartigimod argenx nipocalimab momenta alexion rozanolixizumab ucb note alexion
collabor affibodi anoth fcrn asset though clinic data present yet similar mode-of-act fcrn
inhibitor differenti abil reduc total igg level safeti profil rout administr stage develop
overal view fcrn inhibitor immunov argenx momenta leader space reason describ immunov
may desir profil consid combin rout administr igg reduct safeti profil howev
given number indic igg-medi expect one winner class
total igg reduct exact translat igg reduct therapeut benefit remain unknown gener believ
greater decreas autoantibodi lead greater patient improv across igg mediat condit phase studi healthi
volunt momenta lead pack mean igg reduct dose iv nipocalimab sc data yet immunov
come close second mean reduct dose sc rest fcrn inhibitor develop
present igg reduct roughli note momenta immunov potent reduct across
igg subtyp well
safeti profil whole fcrn class well toler patient although distinct differ safeti profil
asset could affect market uptak competit field exampl ucb alexion asset led dose depend
increas headach led treatment discontinu ucb mg trial albumin decreas seen therapi
momenta immunov ucb ucb describ modest isnt surpris given fcrn also respons recycl
albumin albumin reduct associ around lower rang normal associ aes/
clinic symptom major kol spoken concern ae given structur argenx seen
albumin reduct dose-depend rate headach studi
rout administr compani develop fcrn inhibitor race develop sc formul kol note prefer
roa iv administr larg major indic asset develop anti-fcrn alreadi
optim sc therapi addit fast minim invas strong igg reduct seen sc
hand argenx collabor halozym work offer potent sc formul efgartigimod plan test
one three formul futur studi mg/kg iv via minut infus mg sc mg/kg iv induct follow mg
sc mainten ucb alreadi develop sc form rozanolixizumab infus take administ momenta
alexion note sc formul product expect enter clinic soon data present yet
note iv dose went mg/kg mad given magnitud igg reduct may decreas go iv sc
formul believ best sc pk/pd class
stage develop detail stage develop fcrn inhibitor slide report believ immunov
well posit expect first in-class go well earli mover waiha
current fcrn inhibitor develop go grave ophthalmopathi go autoimmun disord
bodi produc igg autoantibodi bind activ thyroid-stimul hormon tshr insulin-lik growth
receptor lead sever inflamm ocular orbit tissu earli diagnosi therapeut intervent activ phase
diseas decreas sever associ symptom proptosi doubl vision etc need surgeri later stage go inhibit
fcrn-igg interact expect minim effect autoantibodi thought drive diseas progress
horizon teprotumumab fulli human mab bind extracellular portion demonstr statist
signific improv proptosi clinic activ phase ii phase studi loos provid mechanist rational fcrn
inhibitor addit compani project peak net us sale asset demonstr market potenti target therapi
go kol believ fcrn inhibitor potenti effect tepro without associ name hyperglycemia
diabet patient moreov given prefer subcutan roa tepro iv kol note potenti first-in-class
anti-fcrn therapi primari first-lin treatment option diseas neuro-ophthalmologist infus center within
clinic data open-label phase iia studi expect quarter data random phase iib trial come
earli current estim world-wide sale go risk-adjust calendar year end march
myasthenia gravi igg driven diseas fcrn inhibit partial valid posit random data
myasthenia gravi mg autoimmun disord postsynapt neuromuscular junction nmj character fatig weak involv
variabl combin ocular bulbar limb respiratori muscl signific impact qualiti life mg estim affect
patient us eu diseas patholog mediat pathogen igg autoantibodi bind compon nmj
commonli acetylcholinesteras receptor achr roughli gener mg gmg patient treatment like cholinesteras
inhibitor corticosteroid immunosuppress immunomodul agent plasma exchang ivig activ roughli
patient uncontrol diseas patient consid refractori alexion soliri dose iv
approv fda treat achr gmg compani note gmg success drug launch date despit
typic reserv refractori patient given annual cost
current assess phase iia studi gmg patient studi expect readout pivot phase
trial plan begin later year base posit random phase ii data compet anti-fcrn therapi name argenx
believ high likelihood succeed clinic studi given level igg reduct across subtyp subcutan
roa expect readili use mg despit competit natur market note fcrn inhibitor mechanist
also expect work achr-neg patient expect class captur larg portion mg market current estim
world-wide sale mg risk-adjust calendar year end march
waiha remain ration indic fcrn inhibitor warm autoimmun hemolyt anemia waiha immun condit
character product autoantibodi erythrocyt antigen normal bodi temperatur lead red blood cell
destruct promot degrad igg subtyp fcrn inhibitor potenti reduc quantiti
autoantibodi drive progress diseas minim degre hemolysi patient-experi given lack clinic data
kol spoke note earli differenti pipelin therapi develop would fit
treatment paradigm howev optimist anti-fcrn believ clinic potenti base mechan
respons itp base avail respons relaps rate kol also indic patient treat multipl novel therapi
cours diseas leav room multipl winner space current estim world-wide sale waiha
risk-adjust calendar year end march
inhibitor igg driven diseas
alpha seri
lifesci capit alpha seri intend encompass high conviction/impact idea within healthcar sector analys
recommend base deep fundament analysi goal help creat alpha investor long run
twelve-month price target base dcf valuat start slide assum discount rate termin growth
rate million fulli dilut share assumpt follow
grave ophthalmopathi go believ enter market go early-mid reach global sale
calendar year end march risk-adjust estim start annual net-cost therapi us
analysi assum peopl us activ moderate/sever go patient receiv novel therapi base
comp market expect fcrn inhibitor enter go market success estim class captur
market novel therapi given potenti best-in-class profil first-to-market advantag expect
captur fcrn market indic
myasthenia gravi mg believ enter market mg early-mid reach global sale
calendar year end march risk-adjust estim start annual net-cost therapi us
analysi assum peopl us mg gmg patient achr diseas
popul mg treatment develop focus note fcrn inhibitor could work mg patient achr-
less sever given moa provid potenti upsid assumpt overal estim patient well control
avail therapi refractori standard treatment group could elig receiv fcrn
inhibitor given competit environ mg drug develop estim fcrn inhibitor use uncontrol
patient captur market class note estim could conserv profil
posit differenti enough time mg fcrn inhibitor move earlier line therapi
warm autoimmun hemolyt anemia waiha believ enter market waiha early-mid
reach global sale calendar year end march risk-adjust estim start annual net-cost
therapi us analysi assum peopl us waiha relaps steroid patient
typic treat rituximab estim patient relaps treatment sinc sever treatment
modal develop waiha estim fcrn inhibitor use patient given lack clinic data
current assum three fcrn inhibitor develop waiha equal captur market share although assumpt
like chang addit clinic data
platform valuat broad therapeut potenti
target fcrn extend beyond current indic focu
immunov incorpor valu assign platform premium dcf note percentag may chang
base result current studi
expens estim cog revenu time launch decreas calendar year end march
estim expens declin time launch reach calendar year end march estim
market sg expens repres revenu calendar year end march
scenario analysi upsid base case downsid
sale surpass expect one indic
clinic trial demonstr safe effect
autoimmun condit includ revenu build
compet program delay gain regulatori approv
initi launch mg go waiha
achiev global risk-adjust sale non-risk-
adjust calendar year end march respect
fail achiev posit result futur clinic trial
obtain regulatori approv
market target develop
expect result sale estim
risk invest
consid invest immunov high-risk reason limit follow
clinic immunov valuat depend upon success outcom on-going clinic studi
prior data highlight drug safeti pk/pd profil number patient report limit may
predict futur clinic success
regulatori clinic develop regulatori risk surround develop despit
signific time financi invest guarante therapi reach market
market despit belief potenti becom differenti therapi treatment paradigm
go mg waiha product clinic develop may compet sale may
ultim meet project
price reimburs formulari placement payer restrict prior author step edit
could significantli impact potenti sale achiev addit price treatment may
maintain time particularli ex-u increas price pressur
financ immunov may need rais addit capit dilut financ may abl obtain
suffici capit fund plan develop program market launch
tabl content
background
treatment
treatment
treatment
model
analyst certif disclosur research rate
immunov imvt clinical-stag biopharmaceut compani base new york focus develop subcutan
fcrn inhibitor patient suffer igg mediat autoimmun condit includ grave ophthalmopathi go phase
ii myasthenia gravi mg phase ii warm autoimmun hemolyt anemia waiha phase ii studi expect start earli
believ potenti best-in-class profil given subcutan deliveri phase data show favor
safeti profil strong igg reduct across subtyp reduct mg dose level healthi volunt
competitor fcrn space inconsist igg reduct across subtyp clinic meaning ae
headach and/or difficulti formul subcutan product desir pk/pd properti
immunov becam publicli trade compani via busi combin agreement health scienc acquisit
go kol believ fcrn inhibitor mechanist rational safe effect teprotumumab lead asset
develop diseas posit random phase data given prefer roa sc vs iv tepro
potenti first-in-class fcrn therapi indic prefer first-lin treatment option diseas
mg igg driven diseas affect postsynapt neuromuscular junction nmj fcrn inhibit partial valid
posit data argenx efgartigimod ucb rozanolixizumab also hit stat-sig mg-adl
promot degrad igg subtyp
potenti reduc quantiti autoantibodi drive progress
waiha minim degre hemolysi patient experi
earli kol believ fcrn inhibitor clinic potenti diseas
base mechan respons idiopath thrombocytopen
term hsac transact
share
upcom catalyst immunov competitor
addit compani mileston believ catalyst within therapeut area
fcrn space whole could meaning impact potenti asset
top-line result phase iia studi
top-line result open-label phase iia studi
top-line result random phase iib studi
top-line result phase iia studi
top-line result phase studi efgartigimod
top-line result phase ii studi nipocalimab
top-line result phase ii/iii studi nipocalimab
argenx momenta horizon immunov compani present press releas
public comp immunolog space
share price
background
pathogen autoantibodi autoimmun diseas
antibodi aka immunoglobulin glycoprotein secret cell play
import role recognit neutral pathogen via complement
antibodi depend cytotox opson phagocytosi
variabl region fab antibodi recogn antigen constant
region fc interact member immun system remov
matur process immatur cell screen central toler
base affin receptor complex broadli express molecul
stromal cell bone marrow shown right
gener cell autoreact specif elimin via apoptosi
neg select non-autoreact enter matur
immatur b-cell autoreact may undergo receptor edit via
reactiv recombinas machineri potenti spare elimin
autoimmun diseas howev cell recogn antigen normal cell
pathogenesi autoimmun diseas complet understood
genet suscept environment trigger thought play role
accord american autoimmun relat diseas associ
aarda american suffer one autoimmun diseas
aarda autoimmun diseas statist cell develop activ effector function primer immun respons grimaldi et al journal immunolog
differ type immunoglobulin
five primari class immunoglobulin shown distinguish type heavi chain found molecul
differ heavi chain polypeptid allow antibodi particip variou stage immun respons
igg preval antibodi serum non-mucos tissu major effector molecul humor immun respons
igg group subclass base slight differ amino
acid sequenc heavi chain alter immun complex format complement activ effector cell trigger half-lif
total serum ig
parasit allerg
respons involv
releas histamin
present surfac
 cell
function antigen
protect wall bronchi
small intestin
secret mucu tear
respons restrict
bloodstream due
mucu secret
saliva
schroeder cavacini journal allergi clinic immunolog thermo fisher scientif immunoglobulin structur class
fcrn facilit transport recycl igg
neonat fc receptor fcrn
fcrn mhc class i-rel molecul play signific role
transport recycl pinocytos igg shown right
fcrn broadli express mammal found throughout
bodi promin vascular endothelium
albumin also natur ligand fcrn homeostasi
regul receptor similar manner igg
unlik mhc class molecul fcrn present antigen
t-cell due point mutat disrupt peptid bind
fcrn bind fc portion igg ratio acidifi endosom
ph protect antibodi lysosom catabol
igg transport across cell recycl back
surfac fcrn dissoci physiolog ph
result igg serum half-liv day compar
coupl hour day circul protein
modul fcrn-igg interact novel therapeut extend
pk benefici antibodi shorten half-lif pathogen one
monoclon antibodi inhibit fcrn prevent recycl igg back circul reduc antibodi half-lif
therapeut potenti transform treatment autoimmun diseas mediat pathogen igg antibodi
roopenian natur review immunolog sockoloski szoka advanc drug deliveri review toh et al journal cell scienc
target fcrn potenti multipl igg-medi diseas
fcrn inhibitor shown significantli reduc igg concentr healthi volunt patient turn expect
allevi symptom multipl autoimmun diseas proof concept alreadi establish variou igg-medi diseas
includ myasthenia gravi mg immun thrombocytopenia purpura itp pemphigu vulgari pv
immunov highlight multipl igg-medi diseas fcrn inhibitor may clinic benefici argenx also
note fcrn inhibitor may efficaci scleroderma lupu multipl sclerosi anca vascul bullou pemphigoid other
mani indic alreadi treat lower pathogen autoantibodi via immunoglobulin therapi ivig
immunoadsorpt plasmapheresi rituximab establish rational fcrn inhibitor approach
list exhaust
necessarili repres
compani target
indic
immunov compani present press releas zuercher et al autoimmun review
fcrn inhibitor significantli improv current standard
mani autoimmun diseas target therapeut yet exist instead treatment approach broadli suppress immun respons
commonli use though associ signific limit advers event profil shown
filtration/dialysi remov
antibodi plasma
return rest back bodi
highli invas non-
specif form treatment
inconveni patient
treatment day
hospit
high risk viral infect
carri price tag
highli purifi igg deriv
larg pool human plasma
decreas inflamm
high protein burden
hospit day
potenti signific
high risk viral infect
high price tag given
link signific
therefor taken
prolong period time
despit disadv global
ivig market estim
compound-annual-growth-rate
kol note
mab
inhibit activ
differenti cell
physician often deal
reduc plasma cell
level secret antibodi
slow onset clinic efficaci
take week
pyrexia anemia
class fcrn inhibitor potenti offer patient igg-medi autoimmun diseas efficaci
conveni toler form diseas manag compar current approach
fulli human mab target fcrn
develop treatment igg-medi autoimmun diseas
asset current phase ii develop grave
ophthalmopathi go myasthenia gravi mg warm
dec roivant acquir exclus licens develop
market asset aka hanal biopharma krx
us eu uk switzerland latin america mena
addit up-front payment hanal potenti
receiv mileston payment mid-singl mid-
teen royalti net sale
unlik fcrn inhibitor design
incept sc inject use ligand pharma
backbon engin reduc effector function limit
risk immunogen unintend immun respons
first fcrn inhibitor optim sc deliveri rather iv sc infus demonstr
potenti best-in-class sustain igg reduct sc inject without need iv induct phase result cover next
immunov roivant compani present press releas
american academi neurolog annual meet immunov present phase data evalu safeti
pharmacokinet pharmacodynam singl repeat dose administ via sc inject iv infus
healthi volunt dose schedul sad mad cohort shown
immunov compani present press releas present
treatment result meaning igg reduct
total igg reduct increas dose-depend manner shown figur nadir approxim
day singl dose median time peak drug concentr rang less day lowest dose day highest
activ acid physiolog ph lead robust fcrn inhibit sustain igg reduct
mad cohort four weekli dose sc result reduct igg respect
without need iv induct igg reduct sustain one month last dose
kol note potenti lead fcrn inhibitor clinic given signific igg reduct eas
use would allow at-hom administr
mean total igg reduct singl left multipl sc dose right volunt
immunov compani present press releas present
lead strong reduct igg subtyp
shown similarli reduc concentr without meaning chang igm iga level
potenti translat clean safeti efficaci profil across multipl indic driven differ igg subtyp
fcrn inhibitor develop lead consist igg reduct across subtyp could affect clinic efficaci certain diseas
immunov compani present press releas present
safeti profil look date
gener well toler follow singl multipl
ascend dose healthi subject treat placebo total
subject phase studi
mild moder sever patient discontinu
treatment prematur due ae
sae case cancer append observ separ
sad cohort rule unrel therapi
common mild inject site erythema swell
dose relat resolv within hour similar isr
incid rate report treatment control arm
report frequent placebo pool
safeti popul includ headach dose-depend upper respiratori
infect oropharyng pain insomnia
tabl report across phase sad
mad cohort found next slide
low-tit anti-drug antibodi ada observ patient
receiv subject baselin ada placebo
subject mad cohort develop ada week last dose
note patient receiv humira clinic studi develop ada
immunov compani present press releas present nih genet diseas
kol focus albumin decreas
similar igg albumin homeostasi regul fcrn
therefor mani fcrn inhibitor expect reduc
serum concentr protein well
dose-depend revers asymptomat reduct
albumin observ phase trial
seen fcrn therapi san argx
day albumin level g/l
g/l cohort respect
kol note albumin level still near lower
end normal level g/l reduct
associ clinic symptom
addit patient congenit analbuminemia
rare genet disord character absenc low
level albumin signific
kol note patient suffer diseas
gener asymptomat apart eas
fatigu ankl edema hypotens
advers event report phase studi
immunov compani present press releas present
multipl anti-fcrn develop igg-medi diseas
argenx top-line phase data expect
ucb top-line phase data expect
immunov top-line phase ii data expect
momenta top-line phase ii data expect
alexion potenti initi phase ii studi
immunov top-line phase iia result expect
momenta top-line phase ii/iii data expect ye
alexion initi phase ii studi earli
argenx first phase studi initi readout indic
ucb phase ii recent complet initi phase indic
ucb phase ii studi initi readout indic
argenx phase ii studi initi readout indic
argenx top-line phase ii data expect
momenta phase ii proof concept data expect
immunov top-line phase iia open-label result phase iib random result
argenx ucb momenta alexion immunov compani present press releas
hdfn hemolyt diseas fetu newborn
overview clinic fcrn inhibitor
fcrn affibodi
rout admin
volunt
mad
sc dose
sc iv
mad
dose
phase data
sc enhanc
signific rate
littl known
increas ck
min signific rate
momenta day argenx ucb momenta alexion immunov compani present press releas
iv sc dev
iv sc dev
dose
sad
iv sc
top-line thought fcrn inhibitor develop
fcrn inhibitor creat equal obvious bullish mechan fcrn inhibitor use treat
variou igg-medi diseas howev believ program key differenti aspect set apart includ
efgartigimod due uniqu structur efgartigimod associ safeti concern observ
fcrn inhibitor develop includ headach albumin reduct ck elev asset advanc pipelin
potenti first-in-class therapeut mg cidp itp pv
nipocalimab ck elev uniqu asset compani think tx relat iv nipo demonstr
largest igg reduct healthi volunt may translat enhanc efficaci patient given potenc believ
nipo dose less frequent iv infus via sc inject asset fcrn inhibitor develop hdfn
asset anti-fcrn alreadi optim sc administr without need iv load dose
kol note key differenti patient addit demonstr similar igg reduct nipocalimab
healthi volunt well posit first-in-class go earli mover waiha
less enthusiast rozanolixizumab asset led dose-depend increas headach
treatment discontinu ucb mg trial addit pronounc effect may limit
potenti diseas rozanolixizumab also administ via sc infus min rather inject given
fcrn inhibitor market competit believ disadvantag could limit commerci opportun asset
affibodi remain question mark addit small size kda vs kda mab interest
structur expect longer half-lif current anti-fcrn develop given tether albumin bind domain
howev much els known program still earli develop approv affibodi molecul date
efgartigimod human igg fc-fragment develop abdeg fc-engin tech increas affin fcrn acid
physiolog less ph asset expos fc tail therefor reduc fc receptor engag immun stimul
asset current phase clinic develop mg phase ii trial itp pv cidp
safeti pk pd iv efgartigimod assess placebo-control phase studi healthi volunt
sad cohort igg reduct day iv efgartigimod signific reduct class antibodi
mad cohort efgartigimod demonstr mean igg reduct dose potent reduct across igg subtyp
slightli lower effect igg level remain reduc three week return baselin month
singl ascend sad multipl ascend dose mad phase studi volunt
ulricht et al journal clinic investig argenx compani present press releas
number healthi subject phase studi
shown right efgartigimod safe gener well
toler sad mad portion studi
treatment-rel seen subject
high dose therapi
one sae hyperventil report subject
day receiv first infus mg/kg
consid unlik relat treatment
count increas c-reactiv protein level note
subject deem mild sever
mention earlier administr singl dose
efgartigimod induc decreas iga igd ige
igm limit risk infect
addit efgartigimod influenc albumin
homeostasi either anim phase studi
posit titer detect sad mad cohort
efgartigimod link develop ada
new safeti signal observ efgartigimod
phase ii mg itp clinic studi
ulricht et al journal clinic investig argenx compani present press releas
argenx also run addit phase trial evalu sc formul efgartigimod healthi individu singl dose
treatment arm sc efgartigimod compar half-lif pd toler iv formul bioavail
initi iv dose follow weekli sc inject efgartigimod demonstr reduct igg steadi state
compani explor iv sc dose schedul mg/kg iv mg sc mg/kg iv induct follow mg sc
on-going studi collabor halozym co-formul sc efgartigimod enhanz technolog order
reduc volum inject drug administr time
enhanz base recombin human hyaluronidas enzym local degrad hyaluronan ha
sc space allow increas dispers absorpt co-administ therapi volum ml
phase studi demonstr compar characterist sc iv efgartigimod
ulricht et al journal clinic investig argenx compani present press releas
human anti-fcrn mab origin develop syntimmun alexion acquir syntimmun sep
up-front payment potenti mileston
alexion plan initi phase ii studi waiha phase studi sc formul healthi volunt
earli base result compani also plan initi phase ii studi sc formul gmg
syntimmun recent publish data random sad phase ia studi healthi subject mg/kg
reduct igg circul immun complex cic observ five day singl dose mg/kg
albumin iga igm level significantli alter
headach common patient mg/kg cohort determin mild moder sever
syntimmun alexion pharmaceut compani present press releas blumberg et al scienc advanc
addit alexion announc identifi impur drug relat manufactur step result
discontinu multipl phase ib/iia trial preliminari data first cohort lowest dose studi shown
phase ib/iia waiha studi igg reduct dose weekli week
phase ib/iia pemphigu vulgari pv /foliaceu pf studi igg reduct dose weekli week left fig
phase healthi volunt studi igg reduct dose weekli week
drug discontinu interrupt dose reduct report phase ib/iia pv studi shown figur right
sae diseas exacerb acut kidney injuri deem unrel treatment
headach common ae happen first infus deem mild moder
administ top soc corticosteroid immunosuppress
syntimmun alexion pharmaceut compani present press releas
bival antibody-mimet affibodi design affibodi platform
high bind affin fcrn effici autoantibodi reduct
given small size kda vs kda mab
potenti administ high dose low volum sc inject
addit expect longer half-lif anti-fcrn
antibodi due tether albumin bind domain
howev kol note potenti immunogen sinc
asset mimet rather natur occur molecule/protein
much disclos preclin studi demonstr
affibodi molecul fuse albumin bind domain reduc igg level
data necessari compar on-going fcrn-inhibitor program
march alexion partner affibodi up-front
mileston tier low double-digit royalti co-develop
alexion lead clinic develop commerci product
affibodi option co-promot therapi us lead
clinic develop undisclos indic
double-blind placebo-control sad/mad phase studi current on-going
uk assess safeti pk pd determin optim therapeut dose
futur studi healthi volunt data expect
seijs et al natur scientif report alexion affibodi compani present press releas
igg reduct mice affibodi
zfcrn-abd zfcrn albumin bind domain
disclaim known whether molecul discuss
nipocalimab igg reduct phase
sad top mad bottom cohort
nipocalimab fulli human aglycosyl mab develop use
compani proprietari shm-xel antibodi engin technolog higher
bind affin fcrn receptor inhibitor develop
asset epitop specif igg bind site effector function
similar bind strength normal acid ph level
nipocalimab evalu three on-going phase ii trial gener
mg vivacity-mg hdfn waiha
safeti pk pd nipocalimab assess random singl
multipl ascend dose phase studi healthi volunt period
sad cohort mg/kg test clear dose respons full
receptor occup demonstr igg reduct highest dose
mad cohort test dose achiev
sustain receptor occup mean igg reduct similar
reduct observ across igg subclass
given nipo potenc momenta assess possibl less frequent iv infus
monthly/bi-monthli administr test mg sc form therapi
note momenta also develop hypersialyl igg shown
increas potenc vs convent ivig preclin model initi clinic data
phase i/ii studi healthi volunt itp patient expect
momenta compani present press releas
nipocalimab gener well-toler seriou report similar ae rate treatment placebo arm dose
discontinu base conserv threshold low igg first mad cohort discontinu occur second dose
asymptomat recover albumin reduct note sad cohort dose mad cohort
three subject lowest dose mad cohort creatin kinas ck elev also alt elev
asymptomat recover subject receiv dose note momenta believ ck elev drug relat
momenta compani present press releas
igg reduct singl dose sc top iv bottom
rozanolixizumab volunt
rozanolixizumab human mab
backbon target fcrn high affin
asset on-going ph studi mg ph ii
cidp recent complet ph ii studi itp
pk/pd safeti profil
rozanolixizumab iv sc infus healthi
individu evalu placebo-control phase studi
igg concentr reduc
singl dose sc iv cohort
observ igg reduct persist week
maxim reduct occur day return
baselin day
reduct pronounc dose-
depend decreas igg subclass observ
sc iv infus
note six dose sc rozanolixizumab shown
reduc serum igg random double-blind
proof concept phase iia studi mg
kiessl et al scienc translat medicin ucb compani present press releas
ae profil phase studi across doses/rout
administr rozanolixizumab shown right
patient treatment arm
patient placebo arm report
common treatment arm
pyrexia
report headach back pain report
support higher exposur drug healthi subject
report consid mild
moder intens resolv
treatment emerg headach preval
concern rozanolixizumab fcrn inhibitor
phase iia mg studi treat patient
experienc headach vs placebo
headach resolv therapi three patient
treatment arm withdrawn studi
per protocol result headach
kiessl et al scienc translat medicin ucb compani present press releas
publish role
fcrn sinc
role develop one
anti-fcrn therapi
fcrn target treatment want igg reduct big enough drive diseas benefit
ph depend effect fcrn lead longer half-lif therapeut antibodi lifesci note
said sc dose like weekli agent develop
mention rituximab kill express cell direct effect plasma
cell also creat igg autoantibodi
plasmapheresi consid expens tediou lead signific decreas circul
igg plasmapheresi clear igg tissu fcrn inhibitor
ivig suppli shortag issu signific associ heterogen high dose
need outcompet autoantibodi fcrn
note fcrn express throughout bodi lot liver macrophag believ
import site fcrn mediat salvag endotheli cell doesnt think advantag sc
deliveri traffick better lymph node vs iv
didnt seem concern immunogen anti-fcrn affibodi sinc igg lower referenc
murin antibodi approv use organ transplant target cell
relev igg subtyp igg vari diseas
treatment grave ophthalmopathi
overview grave ophthalmopathi go
go autoimmun diseas bodi produc igg autoantibodi bind activ thyroid-stimul
hormon tshr insulin-lik growth receptor lead inflamm ocular orbit tissu
earli diagnosi intervent activ phase diseas decreas perman tissu scar within eye
inhibit fcrn-igg interact potenti minim downstream effect tshr
autoantibodi drive progress go target approach immunosuppress
agent current use favor roa horizon teprotumumab sc vs iv
assess two on-going phase ii studi top-lin result ascend-go open-label expect
top-lin result ascend-go random placebo-control expect earli
competitor standpoint teprotumumab goal pdufa date march
estim patient us everi year activ moderate/sever form go estim
treat novel therapi teprotumumab fcrn inhibitor- assum other develop captur
market assumpt lead risk-adjust non-risk-adjust us sale respect
also model rest world sale base comp ophthalmopathi space global probabl adjust sale calendar
grave ophthalmopathi go
grave ophthalmopathi aka thyroid diseas grave orbitopathi
autoimmun condit character inflamm ocular orbit tissu
diseas annual adjust incid rate women men per
individu compani estim
patient us activ go everi year
go commonli occur patient grave diseas gd autoimmun
disord bodi produc igg autoantibodi bind stimul
thyroid-stimul hormon receptor tshr result hyperthyroid
note tshr highli express ocular fibroblast adipocyt
less common go also occur patient euthyroid
common go symptom result
eyelid swelling/retract feel retroocular discomfort pressur
symptom affect vision patient experi sight-
threaten form go due corneal exposur compress optic neuropathi
barrio-barrio et al journal ophthalmolog mcalinden vision liabo et al univers iowa health
pathophysiolog grave ophthalmopathi
underli pathogenesi go complet understood
presum mechan driven develop autoimmun tshr
shown figur right
antigen-pres cell recogn tshr express thyroid follicular
endotheli cell orbit fibroblast activ helper cell
cytokin ifn- secret activ helper cell activ
 cell secret tshr autoantibodi
igg autoantibodi stimul tshr lead increas product
thyroid hormon primarili recognize/attack orbit tissu
orbit fibroblast stimul ifn- tnf- growth factor secret
hyaluron acid/prostaglandin known mediat inflamm
subset fibroblast may differenti matur adipocyt present
tshr result increas synthesi glycosaminoglycan
caus edema orbit structur muscl enlarg tissu expans
igg antibodi insulin-lik growth factor receptor express
orbit fibroblast also believ stimul secret chemokin
enhanc recruit cell lymphocyt macrophag mast cell
inhibit fcrn-igg interact expect minim
effect tshr autoantibodi drive progress go
bahn new england journal medicin smith et al best practic research clinic endocrinolog metabol huang et al
go biphas cours diseas
unlik autoimmun diseas go consid self-limit given absenc lymphoid tissu within orbit go follow
biphas cours activ phase rapid inflamm follow partial regress inactive/st phase shown
averag activ phase go tend last year nonsmok year patient expos smoke
activ phase reoccur patient unlik happen inact phase month
long-last muscular edema increas product collagen associ inact phase go ultim lead atrophi
fibrosi sclerosi extraocular muscl limit movement eye
earli diagnosi intervent activ phase decreas degre perman tissu scar within eye
surround tissu prevent sever manifest diseas enhanc long-term outcom patient
barrio-barrio et al journal ophthalmolog mcalinden vision liabo et al univers iowa health
metric evalu sever activ level go
sever classif develop assess clinic manifest
go nospec primarili use measur clinic sever diseas
class physic sign symptom
class ii soft tissu involv swell tissu around eye
class proptosi bulg eye socket
class vi sight loss usual due optic nerv involv
hand clinic activ score ca discrimin
activ quiescent stage go help monitor symptom
diseas recurr follow-up approv endpoint go studi
one point given presenc paramet list right
diseas consid activ ca initi examin
follow
appear european group grave orbitopathi eugogo
classif ground nospec ca system
ca paramet initi examin score
eyelid swell consid due
activ go
conjunctiv red consid
due activ go
inflamm caruncl plica
follow-up examin score
increas proptosi
decreas uniocular ocular excurs
one direct
decreas acuiti equival snellen line
mourit et al british journal ophthalmolog barrio-barrio et al journal ophthalmolog
correl tshr autoantibodi level go activ
shown figur signific correl observ ca tshr autoantibodi measur tsi left
tbii right assay serum patient untreat sever go
tsi repres level tsh-receptor stimul immunoglobulin tbii indic tsh bind inhibit immunoglobulin
weaker signific correl also note proptosi tbii tsi howev
tsi tbii titr correl diseas durat eye muscl motil
correl prove causat studi provid rational novel therapeut like meaning
reduc clinic activ clinic symptom go reduc level tshr autoantibodi
bahn journal clinic endocrinolog metabol gerd et al clinic endocrinolog
go current treat first-lin
manag go primarili influenc diseas activ
sever well age risk factor associ comorbid
current fda approv therapi go
kol note patient mild diseas improv
within mo need treatment beyond local measur
consid diseas modifi glucocorticoid gc
wide use treatment go reduc inflamm
iv administr gc regard prefer therapi
effect better toler oral administ gc
moder sever go patient respond iv
methylprednisolon vs treat oral
prednisolon doubl blind random clinic trial
iv gc administr also associ fewer shorter
treatment cours lower relaps risk compar oral gc
despit signific oral gc use iv infus
logist possibl kol note cumul dose oral
gc exceed exceed consecut day
overal treatment gc gener discontinu week
clinic respons patient dont respond
first-lin manag go accord
eugogo guidelin
iv dose methylprednisolon week infus
oral dose prednison daili week taper
bartalena et al european thyroid journal marcocci smith thyroid diseas page zang et al journal clinic endocrinolog metabol
go current treat second-lin
second-lin manag go accord
eugogo guidelin
orbit radiotherapi gc
suppress effect lymphocyt fibroblast orbit tissu
reduc product cytokin glycosaminoglycan
valu monotherapi remain controversi combo
gc shown effect either therapi alon
rare risk cataract safe well toler
cyclosporin gc
cyclosporin inhibit product cytokin involv regul
t-cell activ activ suppressor cell
combin cyclosporin gc shown
effect either therapi alon two separ trial
one studi demonstr nonrespond either
prednison cyclosporin posit respons combo therapi
common associ cyclosporin dose-
depend liver renal toxic well gingiv hyperplasia
surgic intervent note go patient requir surgeri
kol note surgeri orbit decompress eyelid/strabismu correct
consid diseas becom inact sight threaten
bartalena et al european thyroid journal marcocci smith thyroid diseas page zang et al journal clinic endocrinolog metabol
ivig plasmapheresi effect treatment go
shown ivig plasmapheresi shown clinic effect albeit smaller studi treatment go
valid mechanist approach howev kol note neither treatment commonli use given
high price tag lack large-scal random data date
remind ivig infus highli purifi
remind plasmapheresi filtering/dialysi
igg deriv larg pool human plasma
patient blood plasma remov antibodi
plasmapheresi follow immunosuppress
week oral prednison cours ivig
similar level clinic benefit
patient experienc success
outcom ivig oral gc respect
respond treatment arm improv
proptosi median
visual acuiti
intraocular pressur
lid apertur
muscl area
shown yield rapid dramat improv
patient sever go
patient demonstr
meaning benefit soft tissu involv
proptosi tonometri visual acuiti
signific reduct size/dens
enlarg extraocular muscl also observ
four patient moder recurr go six
month steroid withdraw success
treat second cours plasmapheresi
baschieri et al thyroid kahali et al clinic experiment immunolog glinoer schrooyen et al hormon research paediatr
rituximab clinic benefit go mix bag
salvi et al illustr potenti benefit vs iv gc
rituximab chimer mab inhibit activ
differenti cell indic go often use
off-label recommend potenti agent
remind rituximab reduc plasma cell level
also secret antibodi express
rtx clinic benefit moder sever go remain uncertain given
conflict data two small single-cent random trial
salvi et al go inactiv compar
iv gc week vs diseas
recurr recurr iv gc
stan et al differ outcom
placebo patient treat show ca
improv week vs placebo
kol note patient salvi et al repres
pop activ vs stabl phase diseas
addit isr associ sever includ
infect optic neuropathi relat immunosuppress
beyond gc approv therapi demonstr clear benefit treatment moder sever go offer
target approach immunosuppress agent favor ae profil rout administr sc vs iv
bartalena et al european thyroid journal salvi et al journal clinic endocrinol metab stan et al journal clinic endocrinol metab
assess phase ii go studi
ascend-go single-arm open label phase iia studi canada evalu safeti toler pd
effect weekli subcutan treatment patient moder sever activ grave ophthalmopathi
dose schedul patient receiv weekli subcutan inject first two administr follow weekli
inject final four administr subject follow week post-treat shown
primari endpoint safeti toler chang baselin level anti-tshr antibodi total igg igg subclass
secondari endpoint chang proptosi pk/pd anti-drug antibodi level
top-lin result
expect
clinicaltri gov immunov compani present press releas
assess phase ii go studi cont
ascend-go random placebo-control phase iib studi us eu evalu safeti
efficaci three dose regimen patient moder sever activ grave ophthalmopathi
dose schedul patient receiv weekli subcutan inject either
placebo week subject follow week post-treat shown
primari endpoint proport proptosi respond studi eye safeti toler
secondari endpoint proptosi respond rate reduct mm chang baselin proptosi ca ophthalm improv
top-lin result
expect earli
clinicaltri gov immunov compani present press releas
teprotumumab fulli human mab given iv bind extracellular portion inhibit signal complex
sourc go therapi receiv orphan drug track breakthrough therapi prioriti review design fda
dec panel independ advisor unanim vote favor tepro pdufa goal date march
phase optic trial tepro met primari secondari endpoint week includ proptosi respond overal
respond rate percent patient ca reduct percent patient mm proptosi reduct baselin
teprotumumab determin well-toler similar ae/sa discontinu rate compar phase ii studi
higher ae rate nausea muscl spasm diarrhea hyperglycemia diabet patient compar placebo
horizon current run open-label optic-x extens trial assess long-term safety/efficaci teprotumumab
patient treat tepro maintain proptosi respons week year treatment phase ii extens studi
horizon project peak net us sale tepro demonstr market potenti target therapi go
proptosi respons reduct mm phase trial
pool analysi phase ii phase optic trial
horizon therapeut compani present press releas smith et al new england journal medicin
mean chang proptosi
improv qol score
ca respons rate
actemra tocilizumab recombin human mab target receptor
proinflammatori cytokin involv t-cell activ
increas express tshr orbit pre-adipocyt fibroblast go
actemra approv rheumatoid arthriti giant cell arter polyarticular
system juvenil idiopath arthriti cytokin releas syndrom
random double-blind spanish studi tocilizumab shown
improv activ sever go corticosteroid-refractori patient
week patient receiv tocilizumab ca
improv least primari endpoint compar
patient placebo arm detail result shown right
larger proport patient remain stabl improv
tocilizumab placebo compon ca proptosi improv
median week compar placebo
number treatment arm twice placebo arm
two consid seriou moder increas transaminas level week
acut pyelonephr week quickli resolv
thu far studi tocilizumab go academ
sponsor unclear whether roch plan pursu indic
kol note unsur whether respons tocilizumab durabl
percent go patient ca improv
week tocilizumab
percent go patient ca week
tocilizumab
actemra prescrib inform atienza-mateo et al annal rheumat diseas perez-moreira et al american journal ophthalmolog
kol insight futur go treatment landscap
physician excit tepro clinic benefit address proptosi
doubl vision associ diseas limit vs steroid
kol believ prescrib first-lin steroid elig
patient given limit treatment window activ go
kol expect effect tepro given mechan note
therapi need reduc proptosi least clinic use
efficaci ae profil similar kol expect
prescrib tepro almost case given eas administr sc
vs iv result decreas overal cost infus center necessari
sc administr meaning advantag neuro-
ophthalmologist infus center within clinic
less effect tepro kol would prescrib
moder patient use tepro sever patient requir instant benefit
kol also note mild go account patient pop
treat includ model could use
group well provid addit potenti upsid
narrow window opportun treat
patient activ phase go would want get
tepro patient quickli possibl
revers diseas process emerg real-world
safeti signal problemat make sens
patient treat steroid
ae efficaci profil similar physician
patient favor fcrn approach tepro drug
self-administ signific alway refer
diabet patient live normal sinc
get car drive get treatment
fcrn approach realli hit chord end user
kol believ fcrn inhibitor mechanist rational safe effect tepro go given prefer sc
roa potenti first-in-class fcrn therapi primari first-lin treatment option diseas
go market assumpt lead non-risk adjust sale
diseas preval diseas annual adjust incid rate women men per individu difficult
determin number patient activ go howev horizon estim patient us activ
moderate/sever form diseas everi year use median model
diseas growth rate assum diseas growth rate line us popul
go patient expect receiv novel therapi kol agre either tepro use exclus first
line set conserv estim novel asset captur market base insight comp market
expect mani physician especi commun clinic adopt tepro standard care slowli especi sinc
corticosteroid cheap comparison
penetr rate model estim split two asset class favor fcrn given sc rout
administr kol note ophthalmologist infus center clinic howev success
go believ fcrn inhibitor may follow therefor estim captur market class
overal estim take year reach peak penetr us
price sinc go rare diseas high unmet need expect price premium biolog larger
autoimmun diseas incorpor annual net cost model assum net price increas
line us inflat rate
continu slide
go market assumpt lead non-risk adjust sale
market entri model assum market entri us assumpt behind follow
random phase ii top-line result go
end phase top-line result go base month took first
patient enrol tepro phase optic studi top-line data
earli file nda go base roughli month tepro top-line data bla file
earli potenti approv launch go
complianc sinc weekli subcutan inject like taken chronic basi activ phase diseas
assign complianc rate order account potenti miss dose
probabl success seen clinic data fcrn inhibitor go believ posit phase ii
data teprotumumab readthrough sinc function inhibit aspect pathway therefor
current assign probabl success stage develop although number like shift base futur clinic data
net us/row sale assumpt lead non-risk-adjust risk-adjust us sale calendar year end
march respect also model rest world sale base comp weve found ophthalmopathi space global non-risk-
adjust risk-adjust sale calendar year end march respect
patient activ moderate/sever popul growth moderate/sever go patien receiv novel patient expect receiv novel penetr rate novel annual net chang price- compliance- us sale probabl success- probabl adjust sale rest world probabl adjust sale global probabl adjust sale januari
endocrinologist
ophthalmologist focus
gd go year
involv develop
clinic trial multipl
therapeut go
sinc institut tertiari referr clinic kol gener treat sever patient gener pop
estim patient mild diseas moder sever diseas manifest
current treatment approach focu mitig symptom local measur name eye drop mild
patient system immun suppress steroid moder sever patient
kol note us physician conserv prescrib steroid european
counterpart given associ patient respond iv oral steroid use
also mention rituximab like benefici therapi steroid-refractori patient
early/act diseas difficult get approv payor given off-label use
kol note physician excit clinic benefit demonstr teprotumumab
first therapi truli address proptosi doubl vision associ diseas limit
hand kol believ data tocilizumab thu far meaning proptosi
reduct limit transient addit larg clinic trial need run clinic use
kol believ fcrn approach go make sens mechanist similar
efficaci tepro note sc administr signific benefit tepro physician
infus center clinic potenti significantli skew clinic use toward
concern potenti off-target effect given igg reduct long period time
kol note would use tepro steroid case given current
treatment practic includ mild patient moder sever patient
director orbit
larg academ institut
co-found
diseas societi pi multipl
trial go
unlik immunolog diseas inflammatori symptom go may resolv
cours diseas eye bulg doubl vision revers via surgeri current
kol note futur therapi need reduc need surgeri revers underli
symptom diseas sinc steroid cheap
kol estim half patient mild diseas need therapi beyond
local measur half moder sever diseas manifest
iv steroid use extens europ kol note us physician prefer watch
wait order avoid associ patient respond steroid treatment
kol note colleagu excit clinic efficaci teprotumumab especi sinc
patient continu improv week week expect use first line steroid
iv administr tepro cumbersom physician patient ophtho
infus center clinic mention patient discontinu treatment result
kol believ fcrn approach clinic promis lower antibodi level reliabl way
potenti impact ocular thyroid compon diseas
similar efficaci toler profil tepro kol note would use
everi elig patient given eas use also expect therapi cheaper tepro well
even effect tepro still reduc proptosi least kol note
would use mild moder patient given sc roa use tepro sever case
treatment myasthenia gravi
overview myasthenia gravi mg
myasthenia gravi debilit chronic autoimmun disord neuromuscular junction caus igg autoantibodi
postsynapt nicotin acetylcholin receptor achr muscle-specif tyrosin kinas musk low-dens lipoprotein receptor-
relat protein patient experi weak fatigu voluntari muscl result slur speech impair swallow
disabl fatigu episod respiratori failur
fcrn inhibit alreadi partial valid posit random data argenx efgartigimod ucb rozanolixizumab also
hit stat sig mg-adl date sc led rapid sustain igg reduct across subclass believ
lead improv symptom patient
current random placebo-control phase iia studi assess mg patient versu placebo top-line
data expect pivot phase trial plan begin
top-line result efgartigimod phase nipocalimab phase ii expect respect
mg rel rare diseas affect peopl peopl us eu
gener form diseas achr gmg patient believ control steroid
treat fcrn inhibitor assumpt lead risk-adjust non-risk-adjust us sale
respect also model row sale base comp global probabl adjust sale calendar ye march
background myasthenia gravi mg
autoimmun disord postsynapt neuromuscular junction nmj normal
transmiss neuron-to-muscl impuls impair prevent autoantibodi
acetylcholin receptor achr muscle-specif tyrosin kinas musk low-dens lipoprotein
character fluctuat weak ocular bulbar limb respiratori muscl effort
induc worsen success period exacerb
ocular weak present new case extend muscl within year
bimod age distribut yo tend younger women older men
treatment includ immunosuppress immunomodul therapi iv
immunoglobulin ivig plasma exchang plex mainten immunosuppress often
necessari mani year sometim life
requir long-term mainten immunosuppress agent variabl appli even among expert
guidelin last updat coordin patient advocaci group myasthenia
gravi foundat america
wide variabl report incid nonlinear increas due awar time incid
per million person year preval case per estim
peopl us eu mg believ affect world-wide
mortal rate improv substanti death per million
due improv intens respiratori care introduct immunosuppress treatment
sander et al consensu guidanc manag myasthenia gravi neurolog hehir mk et al gener myasthenia gravi classif
clinic present natur histori epidemiolog neurol clin
antibodi neuromuscular junction nmj
healthi individu motor neuron releas acetylcholin ach nmj diffus across synapt space bind receptor
muscl cell membran achr enough acetylcholin bind enough receptor sodium channel open muscl depolar
contract
autoantibodi destroy achr cross-link neighbor receptor absorb destroy via complement
activ result less transmiss nerv impuls lead muscl weak
musk antibodi reduc achr cluster releas acetylcholinesteras ach
levin et al myasthenia gravi newer therapi offer sustain improv cleveland clin medicin
achr subunit
patient achr subtyp
helper th regulatori treg cell recogn achr epitop via mhc class ii
exert helper function cell prolifer differenti plasma cell
 cell synthes auto-ab directli pathogen achr via mechan
focal lysi endplat membran via activ complement
direct blockad ach bind site
reduc number function achr caus morpholog chang endplat
membran fatig muscl weak
patient thymic abnorm thymic hyperplasia typic earli onset
thymoma later onset remaind histolog normal atroph thymu
thymic hyperplasia lymphoid germin center gc contain larg number cell form
thymu possibl trigger viral infect inflamm
gc format also link overexpress proinflammatori cytokin well
enhanc -achr express thymic epitheli cell tec recruit peripher
 cell dysfunct treg intrathym auto-ab product
thymoma typic express self antigen achr larg muscl protein titin autoreact
cell escap stimul b-cell respons peripheri
guptil et al current treatment emerg translat therapi new therapeut target autoimmun myasthenia gravi neurotherapeut
pathophysiolog musk mg other
musk-driven mg typic without activ complement compris
fab-arm exchang musk
achr-neg mg patient mg patient
ab pathogen
impact agrinmuskrapsynachr pathway
role cell product pathogen anti-musk ab clear
increas frequenc cytokin
elev b-cell activ factor baff lower frequenc
regulatori cell fab-arm exchang passiv transfer weak
character promin bulbar weak muscl atrophi rel spare
ocular muscl higher predomin femal
typic sever poor respons cholinesteras inhibitor ivig
excel respons b-cell deplet thymectomi may benefici
driven found mg patient favor prognosi
may concurr achr musk ab
musk auto-ab block interact prevent achr cluster caus impair neuromuscular transmiss
ab endplat protein agrin rapsyn cortactin may also play role often concurr achr musk mg
titin-ab present non-thymoma late onset mg rare non-thymoma earli onset mg may activ complement
seroneg mg patient total omg may requir sensit assay cell-bas assay rather convent
radioimmunoprecipit assay tend less sever diseas
guptil maartj et al musk myasthenia gravi monoclon antibodi valenc dictat pathogen neurol neuroimmunol neuroinamm liu et al
major locat symptom myasthenia gravi
ptosi sometim altern one eye
weak eye closur lack facial express
dysarthria nasal speech
dysphagia nasal regurgit due soft palat involv
facial weak difficulti chew due jaw fatigu
neck flexor weak caus head-lag upon lift lie
neck extensor weak manifest posterior neck pain head-
proxim limb weak arm leg
mg disord fatig weak
produc fluctuat symptom
impair cognit social physic
ocular mild gener mg
patient better physic function
moder gener mg
measur disabl depress
captur patient-report
muscl weak often wors later
day exercis
mg patient experienc fatigu
experi myasthen
intercost diaphragm muscl weak caus respiratori failur
accessori muscl usag sometim promin
levin et al paul et al fatigu impact patient myasthenia gravi muscl nerv
diagnosi mg
base histori atyp examin find
confirm diagnosi seroneg mg patient
weak highli variabl
repetit nerv stimul rn use slow rate
pack test ptotic eye sinc neuromuscular
transmiss improv lower muscl temperatur
sensit patient ptosi
variabl provid fals neg posit
diagnosi must verifi addit test
nerv stimul posit motor respons
declin may indic disord
lambert-eaton myasthen syndrom
singl fiber electromyogram sfemg specif
reliabl neurophysiolog test mg impract
seroposit lab confirm achr musk
administr oral cholinesteras inhibitor
block ab present gmg patient
demonstr benefit symptomat weak
omg
achr-ab titer correl poorli diseas sever
patient howev individu antibodi titer
tend go parallel clinic improv
imag studi chest ct mri imag
contrast perform mg patient look
thymoma present mg patient
remain patient hyperplast thymu
one studi patient mg found achr-ab level fell patient improv also
berrih-aknin et al diagnost clinic classif autoimmun myasthenia gravi autoimmun sander db et al chang acetylcholin receptor antibodi
level correl clinic chang myasthenia gravi muscl nerv pp levin et al
medic scientif advisori board msab myasthenia gravi foundat america mgfa develop univers accept
classif grade system manag patient undergo therapi use therapeut research trial
ocular muscl weak may weak eye closur
muscl strength normal mg patient remain
patient progress gener mg gmg within year
mild weak affect ocular muscl may also ocular
muscl weak sever
moder weak affect ocular muscl may also
ocular muscl weak sever
sever weak affect ocular muscl may also
ocular muscl weak sever
defin intub without mechan ventil except
use routin post-operative manag use feed
tube without intub place patient class ivb
muscl may
also lesser
involv
respiratori muscl
may also
lesser equal
involv limb
axial muscl
gilhu ne et al myasthenia gravi subgroup classif therapeut strategi lancet neurol
assess diseas sever
mg-adl qmg critic endpoint patient-report mg-adl emerg
prefer primari endpoint recent clinic trial fda approv
myasthenia gravis-specif activ daili live scale mg-adl
assess impact daili function symptom typic affect gmg ocular oropharyng respiratori extrem function report patient
item assess scale repres normal function repres loss abil perform function total score
differ consid clinic relev
categor scale assess muscl weak report physician
item assess scale repres weak repres sever weak total score
differ consid clinic meaning score consid mild consid moder sever diseas
reflect worst pretreat clinic condit current clinic situat
class accord degre muscl weak class ocular weak class intub subdivis base bodi locat
compon compris qmg mg-adl manual muscl test mmt includ patient histori
score rang affect sever affect differ consid clinic meaning
survey design assess aspect life relat mg complet patient
appropri correl mg-qol mg-specif scale mgc mg-adl mg-mmt
magnitud chang requir indic improv worsen variabl depend mg sever
minim manifest statu symptom function limit weak examin
remiss symptom weak eyelid closur accept weak muscl long term
remiss may although kol suggest closer averag interv diseas onset
remiss year
ocular mg omg mgfa class ocular muscl weak weak eye closur strength normal
facial bulbar limb muscl patient report fatigu strength test normal patient
initi present ocular symptom
manifest myasthen crisi mgfa class seriou life-threaten rapid worsen mg potenti airway
compromis ventilatori bulbar dysfunct requir intub non-invasive ventil avoid intub
patient musk patient experi crisi
refractori mg patient unchang wors corticosteroid least immunosuppress agent
persist symptom side effect limit function patient achr mg consid treatment
sander et al hehir mk et al cutter et al crosssect analysi myasthenia gravi patient registri disabl treatment muscl nerv
type therapi use treat mg
symptomat treatment acetylcholinesteras inhibit increas amount
acetylcholin ach avail neuromuscular junction
immunosuppress therapi glucocorticoid nonsteroid immunosuppress
agent chronic set target underli immun dysregul
 prednison azathioprin mycophenol mofetil cyclosporin
rapid short-act immunomodul treatment
 plasma exchang intraven immun globulin ivig
thymectomi sinc thymu primari site immun sensit achr
complement inhibitor inhibit variou stage complement cascad
play crucial role pathogenesi achr mg
anticholinesteras agent ivig effect rapid short-term control symptom patient requir
immunosuppress point indefinit maintain diseas stabil
pyridostigmin part initi treatment patient dose adjust
need
corticosteroid immunosuppress therapi use patient
met treatment goal pyridostigmin
patient achiev treatment goal corticosteroid dose gradual taper receiv
nonsteroid immunosuppress agent use alon corticosteroid
contraind use initi conjunct corticosteroid
risk steroid side effect high base medic comorbid
nonsteroid immunosuppress agent also ad signific steroid side
effect develop respons steroid inadequ steroid dose
reduc symptom relaps
includ azathioprin often first line among class howev view teratogen us
cyclosporin sae drug interact limit use mycophenol mofetil littl evid efficaci
methotrex tacrolimu littl evid efficaci
taper mo year minim effect amount associ relaps risk
refractori patient may receiv ivig plasma exchang cyclophosphamid
rituximab consid earli option patient musk-mg
thymectomi option minim dose/ durat immunotherapi
patient fail respond
like effect due remov thymic gc
comparison current gmg treatment
remiss
improv
steroid use
mo
efficaci
small
adjuv
benefit wk
remiss
pt diff
time onset
time maxim
nicotin
use last
yr
progress
oral iv
oral iv
liver
comorbid
cushingoid
featur
use
iv daili
iv weekli
studi
ivig
ach chill
infus
lethargi
hour
ivig easier
administ
fewer
best sever
surgeri
mg futur
effect within
year onset
yo
reserv
achr mg
prednison reduc size/numb gc mani comorbid
prednison effect
prednison inact parent drug prednisolon part treatment
initi therapi cholinesteras inhibitor becom inadequ
act alter genet synthesi therebi modifi cellular function
enzym product metabol process reduc
synthesi inflammatori autacoid prostaglandin immune-
excess may lead euphoria psychosi edema mild
limit effect b-cell respons antigen humor immun
recent studi suggest achr-ab lower effect zhang
sustain serum concentr impart neg feedback
hypothalamic-pituitary-adren hpa axi lead adren atrophi
typic well osteoporosi patient
treatment month due inhibit osteoblast function
time prednison may begin serv normal
physiolog requir need modifi case
stress/surgeri taper withdraw medic
mg patient well manag prednison steroid
spare drug requir addit therapi ivig
becker et al basic clinic pharmacolog glucocorticosteroid anesth prog
comparison plasma exchang ivig lower igg
directli remov humor factor
autoantibodi immun complex complement
nonspecif inflammatori mediat
administr purifi igg deriv larg pool
plasma donor
work faster ivig
eas use rel plex still iv
benefit seem sever week seem
insur coverag limit fda approv
impact tissu igg level
morbid need central access
sophist equip need train staff
reduct plasma igg
reduct achr-ab studi
reduct qmg score
reduct overal igg mechanist make sens
reduct achr-ab
reduct qmg score
comparison methylprednisolon alon reduc achr-ab qmg score
data suggest ab reduct could lead clinic meaning efficaci
farmakidi et al treatment myasthenia gravi neurol clin liu et al compar autoantibodi level clinic efcaci doubl filtrat
plasmapheresi immunoadsorpt intraven immunoglobulin treatment late-onset myasthenia gravi therapeut apheresi dialysi zhang et al doubl
first approv gmg year alexion soliri octob
soliri eculizumab termin complement inhibitor monoclon antibodi
bind complement protein inhibit cleavag
prevent gener deposit termin complement complex
neuromuscular junction
complement act neuromuscular junction continu injur muscl
surfac reduc achr contribut symptom muscl weak
soliri pd profil demonstr free concentr mcg/ml
correl complet blockad termin complement activ
approv treatment gener myasthenia gravi gmg adult
patient achr
dose schedul inject mg weekli first week follow
mg fifth dose week later mg everi week thereaft
pk data show steadi state achiev week start eculizumab
treatment accumul ratio
despit blackbox warn seriou meningococc infect gmg alexion best
launch date gener sale across indic annual cost
therapi
requir meningococc vaccin least week prior soliri administr
soliri gmg patient us
note total soliri neurolog patient gmg patient estim base prior quarter growth account recent nmosd approv
soliri label alexion present
soliri phase studi long-term mg-adl data
fda approv base total data present primari endpoint miss stat-sig
rdbpc studi gmg patient refractori
immunosuppress random receiv soliri placebo
week induct follow mainten period
primari endpoint mean chang baselin week mg-
adl total score eculizumab vs placebo
differ stat sig
sensit analys prospect defin analys around
primari endpoint mg-adl achiev p-valu around
mg-adl chang week point soliri arm vs
point placebo arm
qmg chang week point soliri arm vs
point placebo
week improv maintain
reduc exacerb mg-relat hospit rescu
therapi half patient achiev mgfa post
intervent statu remiss
long term efficaci refractori gmg patient
alexion press releas present
rational mg
regardless mg subtyp pathogen igg antibodi attack critic
signal protein nmj
mg method reduc pathogen igg plasma exchang
ivig reduc symptom mg wane benefit time
reduct igg
approach partial valid argenx efgartigimod ucb
novel fulli human monoclon antibodi select
bind inhibit fcrn demonstr preclin clinic trial
abil reduc igg antibodi level
mechanist may abl address musk patient
refractori rituximab therapi well autoantibodi subtyp
attract profil self administ sq inject via
small gaug needl weekli less frequent dose without
associ corticosteroid
signific unmet need gmg patient fail respond
adequ toler multipl therapi gmg continu
suffer profound muscl weak sever diseas symptom
limit function well manag current therapi
compani websit file
assess phase iia gmg studi
ascend-mg random placebo-control phase iia studi evalu safeti efficaci
two dose regimen patient gener myasthenia gravi
dose schedul patient receiv weekli sc inject placebo week subject
option enrol open label extens everi week week follow week post-treat
primari endpoint safeti toler chang baselin level anti-achr antibodi total igg igg subclass
secondari endpoint pharmacokinet chang baselin qmg mg-adl qualiti life measur
top-lin result
expect
clinicaltri gov immunov compani present press releas
overview fcrn inhibitor develop gmg
iv sc test
iv sc test
volunt
sc iv
sad
mad
iv sc
dose
dose
mad
dose
phase ii data gmg
across efficaci
week vs
placebo qmg
mcg mg-adl
data expect
data expect
data expect
data expect
sc formul
argenx ucb immunov momenta alexion compani present
phase ii studi weekli infus
mg/kg efgartigimod led statist signific
sustain improv across efficaci endpoint
note trial includ achr /- patient
patient treatment arm achiev clinic
meaning stat sig improv mg-adl
least week vs placebo
patient treatment arm rapid improv
clear separ placebo first infus
total pathogen igg reduct found
correl clinic improv note larger
sampl size need literatur debat point
return igg level may differenti
plex respons lost week treatment
efgartigimod evalu on-going phase
trial adapt top-line data expect
follow-on open label ph adapt assess
safeti year data expect june
argenx compani present press releas
phase ii baselin popul diseas characterist
argenx compani present press releas
shown pd efgartigimod gmg popul similar phase trial healthi volunt base
reduct across igg subtyp therapi expect effect achr musk mg patient
argenx compani present press releas
similar phase studi efgartigimod safe well-toler gmg patient treatment emerg balanc
treatment placebo arm mostli mild grade sever
death lead discontinu treatment report trial addit igm iga albumin level
affect reduc risk potenti infect
argenx compani present press releas
dose period weekli sc infus placebo mg/kg
rozanolixizumab day week
dose period patient re-random receiv either
mg/kg rozanolixizumab day observ day
convent therapi allow includ corticosteroid
dose period baseline-correct delta vs placebo qmg
mcg mg-adl
mean reduct serum igg igg autoantibodi period
post-hoc analysi show absolut chang baselin mg-
adl score rozanolixizumab vs placebo
respond rate reduct point baselin qmg
vs placebo mgc vs placebo
mg-adl vs placebo
rozanolixizumab current assess random phase studi
achr musk gmg patient top-line result expect
ucb compani present press releas
rozanolixizumab safeti toler remain in-
line sc portion phase trial
phase ii proof concept itp studi
notabl frequenc headach higher
treatment arm vs placebo compar
dose period
headach manag resolv
standard therapi patient treat
rozanolixizumab withdrawn studi per
protocol result ae
incid infect treatment
placebo arm similar
remind nipocalimab demonstr greatest igg reduct fcrn class thu far phase mad cohort mg/kg
nipocalimab achiev mean igg reduct similar reduct observ across igg subtyp
given potenc momenta assess possibl less frequent iv infus monthli bi-monthli dose administr
test mg well sc form therapi much inform provid compani yet
shown nipocalimab evalu treatment gmg random placebo-control phase ii studi vivacity-mg
top-line data studi expect
primari endpoint number particip day chang baselin total mg-adl score day
momenta compani present press releas
shown alexion develop portfolio therapeut gmg help ultomiri cover later
human anti-fcrn mab acquir syntimmun sep remind compani announc
identifi impur drug relat manufactur step result discontinu multipl phase
ib/iia trial preliminari data first cohort lowest dose studi shown
phase ib/iia waiha studi igg reduct dose weekli week
phase ib/iia pemphigu vulgari pv /foliaceu pf studi igg reduct dose weekli week left fig
phase healthi volunt studi igg reduct dose weekli week
alexion plan initi phase studi sc formul healthi volunt earli base result
compani also plan initi phase ii studi sc formul gmg
syntimmun alexion pharmaceut compani present press releas
overview target develop gmg
ra pharma acquir ucb
synthet peptid bind
iv sc formul test
top-line find expect earli
iv sc launch expect
ind submiss studi initi
prefer roa complement
inhibitor daili sc vs iv
eculizumab deeper reduct
qmg/mg-adl anti-fcrn
longer half-lif eculizumab
weekli sc form therapi
develop commerci
structur alreadi place given soliri
express across entireti
b-cell lineag asset
potenti clinic
potent mab
complement inhibitor tend
expens anti-fcrn
complement inhibitor tend
expens anti-fcrn
effect b-cell deplet
gmg disput literatur
enter market later
may lead payor restrict
sc ultomiri assess
may lead payor restrict
expand musk mg
anti-fcrn compound
ra pharma alexion viela compani present press releas
zilucoplan synthet macrocycl peptid bind
high affin inhibit cleavag ultim
prevent overactiv complement system
unlik eculizumab asset shown inhibit variant
may enhanc efficaci
gmg phase ii trial plan immune-
mediat necrot myopathi imnm al
random phase ii studi mg/kg zilucoplan
achiev placebo correct reduct
qmg primari endpoint mg-adl respect
patient qmg improv vs
eculizumab ph efgartigimod ph ii
rescu ivig plasma exchang requir
mg/kg treatment arm
stat sig sustain respons also observ across
endpoint week open-label extens studi
sc qd zilucoplan current assess
top-line find studi expect earli
ra pharma compani present press releas poster present
zilucoplan achiev signific sustain reduct
qmg mg-adl random phase ii studi
mg/kg zilucoplan also achiev statist signific reduct mg
composit placebo correct chang
placebo correct chang week shown
phase ii baselin popul diseas characterist
ra pharma compani present press releas poster present
eculizumab across endpoint pnh
ultomiri ravulizumab-cwvz previous known long-act mab
inhibit protein termin complement cascad
therapi approv us eu jp paroxysm nocturn
hemoglobinuria pnh us atyp hemolyt urem syndrom
ahu inhibit complement-medi thrombot microangiopathi tma
ultomiri amino acid substitut complementarity-determin fc
region result enhanc endosom dissoci recycl
fcrn pathway allow termin half-lif longer eculizumab
largest phase studi complement inhibitor nave pnh patient
ravulizumab administ iv everi week shown noninferior
eculizumab administ everi week across endpoint right figur
alexion note target convers target soliri ultomiri
within two year launch indic
ultomiri current studi phase trial gmg
alexion indic top-line data expect ct gov estim
dec compani expect iv sc ultomiri launch gmg
ultomiri also develop neuromyel optica spectrum disord
al phase primari progress ms ppm phase i/ii
alexion compani present press releas sahelijo et al blood kulasekararaj et al blood
inebilizumab afucosyl human kappa monoclon
antibodi design deplet b-cell circul
remov fucos fc portion molecul also result
increas affin fc receptor significantli enhanc adcc
viela plan submit ind initi pivot trial mg
shown right express across entireti b-cell lineag
express pro-b cell bone marrow plasma cell
contributor pathogen autoantibodi peripheri
therefor inebilizumab potenti clinic potent
mab rituximab ocrelizumab similar safeti profil
base posit data phase n-momentum trial viela submit
bla inebilizumab neuromyel optica spectrum disord nmosd
week treatment inebilizumab reduc risk develop
mosd attack primari endpoint seroposit patient
seroposit agnost patient compar placebo
fda set goal pdufa date june
asset also develop kidney transplant desensit phase ii
alon combin fusion protein
diseas ind submiss phase iib initi
viela compani present press releas sec file
asset develop mg
phase develop
top-line result expect
clinicaltri gov catalyst pharma curavac cartesian cabaletta compani present press releas
moder sever mg
complet data present
top-line result expect earli
complet data present
top-line result expect
indic ind submiss
small proport base steroid spare
major use
rituximab musk refractori
therapi current
futur use fcrn inhibitor highli depend efficaci long-term safeti futur phase studi well price
believ initi use larg line corticosteroid steroid spare agent complement inhibitor
driven price continu market adopt think second line uptak could occur reduc long term steroid use
mg market assumpt lead non-risk adjust sale
diseas preval estim mg preval patient per assum patient us
estim gener mg patient achr diseas popul mg treatment
develop focus note fcrn inhibitor could work mg patient achr- less sever given moa provid
potenti upsid assumpt
diseas growth rate assum diseas growth rate line us popul
mg patient expect receiv novel therapi overal estim patient well control avail
therapi refractori standard treatment group could elig receiv fcrn inhibitor
penetr rate given competit environ mg drug develop estim fcrn inhibitor use
uncontrol patient captur market class note estim could conserv
profil posit differenti enough time mg fcrn inhibitor move earlier line therapi overal
estim take year reach peak penetr us
price sinc mg rare diseas high unmet need expect price premium biolog larger
autoimmun diseas incorpor annual net cost model assum net price increas
line us inflat rate
continu slide
mg market assumpt lead non-risk adjust sale
market entri model assum market entri us assumpt behind follow
phase ii top-line result mg
phase top-line result mg base expect time-frame argenx complet phase
trial mg
earli file nda mg
earli potenti approv launch mg
complianc sinc weekli subcutan inject like taken chronic basi activ phase diseas
assign complianc rate order account potenti miss dose
probabl success strong mechanist rational fcrn inhibitor activ mg class partial de-
risk via posit result random studi other class therefor current assign probabl success
stage develop although number like shift base futur clinic data immunov competitor
net us/row sale assumpt lead non-risk-adjust risk-adjust us sale calendar year end
march respect also model rest world sale base comp weve found autoimmun space global non-risk adjust
risk-adjust sale calendar year end march respect
patient mg growth gmg mg achr patient manag steroids/steroid spare uncontrol mg mg patient use uncontol mg patient expect use fcrn mg patient treat penetr rate fcrn inhibitors- annual net chang price- compliance- us sale probabl success- probabl adjust sale rest world probabl adjust sale probabl adjust sale januari
immunologist focus
cell mechan tissu
damag autoimmun diseas
princip investig
built longitudin biorepositori specimen mg patient
mg autoimmun diseas caus dysregul immun system genet predisposit
howev mg genet studi extrem limit environment factor virus hygien hypothesi
underli mechan achr vs musk mg extrem differ profound impact efficaci
treatment achr ab subclass recruit complement damag
muscl end plate interrupt signal transduct musk ab subclass bind
achr complex channel directli inhibit achr channel cluster complement
help ab result complement inhibitor work well achr mg
musk mg mg involv complement inhibit bind activ
fcrn approach inhibit subclass therefor work mg subtyp includ mg
even seroneg mg actual serum undetect
hyperplast thymu achr mg enlarg contain germin center lymph node
 cell matur becom ab produc thymu cell rituximab studi show plasma cell
bone marrow also produc circul igg thymectomi patient also dont tend complet remiss
clone still present indic bone marrow may nich igg product rather
treat post-thymectomi prednison kol suggest aggress cell deplet therapi
complement inhibitor ra alexion would effect subset patient due
mechan inflict damag inhibit achr bind site antigen modul
immunologist focus
cell mechan tissu
damag autoimmun diseas
princip investig
fcrn trial show ab titer return treatment complet mean therapi would need chronic
lot confus therapi use even patient commit drug
must use long time get result exampl use complement inhibitor patient cant
use rituximab period lot desir creat guidelin mg yet
sq vs iv import patient look ms patient strong prefer therapi
infusion-bas
threshold igg reduct well understood quit import
specialist academ
mg patient involv
patient initi present ocular involv alway includ ab test diagnosi also
includ nerv stimul baselin follow patient singl fiber emg occasion use rule
mg normal patient dont diseas time consum impract also perform
ct scan rule thymoma see perhap patient
diseas cours variabl droopi eyelid short breath icu visit patient
patient respond well treatment cholinesteras inhibitor offer benefit adequ
protect flair show respons within coupl week low dose prednison may
mg may treat mg necessari taper stabl diseas steroid spare agent
cellcept methotrex ad flare goal get minimum manifest rather
complet stabl remiss rarer report closer patient
steroid spare therapi give patient higher level function lower amount steroid
need ivig next option patient often show clear minor improv soliri would
next option kol believ week suffici identifi respond
meaning score includ mg-adl inform manual muscl test determin
strength believ chang mg-adl clinic meaning
argenx data better ucb small dataset patient per arm ra pharma studi includ
patient per arm milder refractori soliri studi program headach
patient went studi ucb common issu biolog
specialist academ
mg patient involv
patient chronic plasma exchang exampl long-term igg reduct rare sinc
usual complic line vascular access difficult say ideal amount igg
fcrn protect igg albumin intern cell anti-fcrn therapi impact
albumin level select enough somehow interfer bind albumin level
reduct dont seem drastic reduct transient littl concern like
unmet need patient experienc doc practic well manag prednison
steroid spare drug patient move onto ivig although feel better ivig well
control ivig soliri remain approv drug eventu replac ultomiri
fcrn therapi like approv use depend clinic trial data cost
less unmet need musk patient treat rituximab
patient receiv iv treatment need get infus facil less issu ultomiri everi
week sq may offer advantag give control patient fewer side effect
thymectomi excel steroid spare effect base clinic trial evid achr mg origin
studi show benefit patient within year diseas onset best surgeri earli possibl
stabl
treatment warm
overview warm autoimmun hemolyt anemia
warm autoimmun hemolyt anemia waiha immun condit character product autoantibodi
erythrocyt antigen normal bodi temperatur lead red blood cell destruct symptom proport
degre anemia patient experi rang fatigu dizzi cardiopulmonari issu death
promot degrad igg subtyp potenti reduc quantiti autoantibodi
drive progress waiha minim degre hemolysi patient experi given lack sustain diseas
control steroid discontinu patient requir addit therapi fda therapi approv waiha
ascend-waiha open-label phase ii studi evalu safeti efficaci two dose regimen
patient waiha fail intoler least one prior line therapi immunov recent file
ind trial expect top-line result
base epidemiolog data well estim immunov momenta rigel pharma estim
case waiha us conserv assumpt sole use corticosteroid rituximab lead risk-adjust
non-risk-adjust us sale respect also model rest world sale base comp weve
found hematolog space global probabl adjust sale calendar ye march
autoimmun hemolyt anemia aiha
aiha immun condit character product
autoantibodi erythrocyt antigen lead red
blood cell destruct without complement activ
lifespan rbc may reduc day
normal condit day sever diseas
etiolog diseas unknown
case idiopathic/primari aiha also occur
manifest underli condit secondari
diseas rare incid preval
per individu respect
symptom aiha proport degre anemia
patient develop anem symptom fatigu
pallor weak dizzi dyspnea
sever form diseas may result jaundic
chest pain splenomegali cardiopulmonari issu death
diseas diagnos presenc hemolyt anemia
elev lactat dehydrogenas ldh indirect bilirubin
level low haptoglobin level serolog evid anti-
autoantibodi via direct antiglobulin test dat
direct antiglobulin coomb test
wash patient rbc incub antihuman igg antibodi
lead agglutin autoantibodi present agglutin grade visual
neg valu indic posit test result
posit dat test neither sensit specif hemolyt anemia
packman medicin hemotherapi qasim immun hematolog pp brodski new england journal medicin
differ type autoimmun hemolyt anemia
aiha classifi three major subtyp base optim temperatur autoantibodi bind patient rbc vivo
drug-induc aiha also possibl extrem rare gener associ cephalosporin cefotetan ceftriaxon
waiha character igg
caiha character autoantibodi
maiha character presenc
antibodi react rbc optim
normal bodi temperatur
commonli associ
time diseas well
pathogenesi waiha
cover detail next slide
waiha common form
diseas compris adult
case pediatr case
attack rbc normal bodi
temperatur includ
driven attack monoclon
igm cold agglutinin result
bind rbc trigger complement
activ cold temperatur
immunov estim
waiha patient
us eu respect
caiha account aiha
cad common form
diseas tend sever
warm igg cold igm
reactiv autoantibodi thermal
amplitud least
diseas often associ
abrupt onset sever hemolysi
difficult determin
autoantibodi caus make
diseas challeng treat
maiha account total
aiha case extrem rare
kol note diseas often
misdiagnos given rariti
packman medicin hemotherapi qasim immun hematolog pp brodski new england journal medicin
detail look pathogenesi waiha
pathophysiolog behind gener autoantibodi primarili igg
bind polypeptid surfac rbc waiha complet understood
believ involv immun dysregul abnorm antigen respons
macrophag spleen commonli express receptor fc region
immunoglobulin allow phagocytosi opson rbc
howev phagocytosi rbc often incomplet portion
membran remov result format spherocyt
subject destruct next passag spleen
antibody-depend cellular cytotox adcc mediat cell nk
cell also directli contribut hemolysi spleen liver lesser extent
high concentr igg high affin complement bound
rbc protein complex bind activ classic complement pathway
erythrocyt lyse kupfer macrophag cell liver
igg weaker complement activ igm igg subclass
activ pathway effici follow
lysi rbc via termin complement pathway possibl rare
promot degrad igg subtyp potenti
reduc quantiti autoantibodi drive progress waiha minim
degre hemolysi patient experi
iga trigger activ complement pathway
berentsen et al therapeut advanc hematolog barcellini medicin hemotherapi kalfa hematolog educ program
waiha current treat first-lin
current fda-approv therapi treatment waiha therapi current use reduc inflamm
tend associ signific halt/compens signific hemolysi associ diseas
like autoimmun diseas diseas modifi
transfus recommend waiha patient requir
therapi waiha patient gener treat gc
first-lin set hemoglobin level reach
immedi stabil due sever anemia hb
order reduc risk pulmonari edema myocardi infarct
recommend dose includ mg/kg/day oral
prednison mg/kg/day iv methylprednison
given associ steroid use
approxim patient achiev clinic meaning
respons week treatment gc addit
therapi ad patient respond time-frame
standard protocol slow taper
sever month usual requir avoid symptomat
relaps complic long-term steroid use
base retrospect studi kol feedback
patient remain remiss discontinu steroid treatment
rest requir addit treatment next slide
patient autoantibodi often caus panagglutin
risk neg reaction abo- rhd-match
blood low patient bee sensit foreign
rbc develop alloantibodi patient histori
previou transfus pregnanc
guidelin recommend initi infus ml blood
follow observ period minut monitor
acut transfus reaction
previous sensit patient donor blood
infus slowli hour patient
monitor sign fever chill dyspnea
brodski nejm hill et al british journal haematolog naik hematology/oncolog clinic north america
clear choic therapi steroid failur
given lack sustain diseas control steroid discontinu patient requir addit therapi howev
recommend treatment base small retrospect studi case report rather random trial
limit studi rituximab demonstr respons rate close
median time respons week associ
signific includ thrombosi infect etc
patient refractori develop signific
steroid may treat immunosuppress agent like
azathioprin mycophenol mofetil cyclosporin
one random studi combin rituximab
prednisolon shown higher rate complet
respons vs steroid alon mo vs
azathioprin alon combo steroid believ
best benefit/risk profil immunosuppress littl
known extent durat efficaci
splenectomi remov spleen
limit studi low-dos oral mg/kg/day
patient refractori diseas respond splenectomi
cyclophosphamid high dose iv mg/kg/day therapi
success sever refractori waiha patient
sustain low-dos steroid may necessari maintain
durabl remiss patient relaps within year
treatment use decad clinic efficaci
rel unpredict associ signific
includ leukopenia teratogen increas neoplasia
surgeri commonli associ bacteri infect
thrombosi vaccin influenza type meningococcu
pneumococcu recommend week surgeri
brodski nejm hill et al british journal haematolog naik hematology/oncolog clinic north america
overview current treatment option waiha
brodski new england journal medicin
note variou guidelin differ
choic second fourth line therapi
establish order
treatment fail corticosteroid
immunov plan assess phase ii waiha studi
ascend-waiha open-label phase ii studi evalu safeti efficaci two dose regimen
patient warm autoimmun hemolyt anemia immunov recent file ind trial novemb
dose schedul patient receiv weekli subcutan inject either dose first demonstr efficaci
placebo week subject follow week post-treat shown
primari endpoint hemoglobin respons rate defin hemoglobin level g/dl least g/dl increas baselin safeti
secondari endpoint chang hemoglobin ldh bilirubin haptoglobin time respons qol pk/pd anti-drug antibodi level
top-lin result
expect
clinicaltri gov immunov compani present press releas
tavaliss fostamatinib disodium hexahydr oral spleen tyrosin kinas inhibitor approv thrombocytopenia patient
chronic immun thrombocytopenia itp asset grant orphan drug design treatment aiha jan
open-label phase ii soar studi waiha patient met primari endpoint hb level
increas g/dl baselin week overal respons rate late respond week includ
new safeti signal identifi initi treatment extens period common diarrhea fatigu
hypertens dizzi trial period subject receiv rescu therapi includ transfus steroid ivig
may rigel enrol first patient random placebo-control pivot phase trial assess safeti
efficaci tavaliss week waiha patient fail least one prior treatment top-line result expect earli
median hemoglobin time phase ii soar studi
rigel believ waiha
potenti
market us demonstr
commerci potenti
target therapi safe
elig patient enter
extens period studi still
treatment
discontinu studi includ
withdrew lost follow
loss respons
rigel pharmaceut compani present press releas abstract
pegyl cyclic peptid administ via sc infus bind
preliminari phase ii data waiha
exhibit broad inhibit complement cascad
develop geograph atrophi ph paroxysm
nocturn hemoglobinuria ph cad ph ii waiha ph ii
eha apelli present preliminari data on-going phase ii
plaudit studi assess safety/efficaci waiha
patient waiha reach day
mean hb increas g/dl baselin g/dl day
mean absolut reticulocyt count arc decreas
baselin day
mean bilirubin decreas mg/dl mg/dl day
mean ldh decreas u/l baselin u/l day
enrol waiha patient left studi due lack
respons yet reach day june
patient show respons note
waiha patient level complement involv
well-toler sae relat treatment report
apelli pharmaceut compani present press releas eha poster
interim data june
nipocalimab human anti-fcrn aglycosyl mab develop use compani proprietari antibodi engin tech
fda grant track design nipocalimab waiha asset also evalu two on-going phase ii
trial gener myasthenia gravi vivacity-mg hemolyt diseas fetu newborn
remind nipocalimab demonstr clear dose respons full receptor occup signific igg reduct
mean reduct day phase studi healthi volunt therapi well toler seriou
momenta believ nipocalimab potenc allow flexibl dose approach compani work assess possibl
shorter durat intraven infus well subcutan form therapi
momenta initi phase ii/iii trial design shown assess safeti efficaci
nipocalimab everi two four week patient waiha top-lin data studi expect ye
primari endpoint number particip attain
hemoglobin respons week
secondari endpoint percent particip
achiev reduct daili dose corticosteroid
maintain hgb respons percent reduct daili
corticosteroid dose hemoglobin rang steadi state etc
clinicaltri gov momenta pharmaceut compani present press releas
human anti-fcrn mab develop syntimmun remind alexion acquir syntimmun
sep up-front payment potenti mileston
alexion plan initi phase ii studi waiha phase studi sc formul healthi volunt
earli base result compani also plan initi phase ii studi sc formul gmg
alexion announc identifi impur drug product relat manufactur step result
discontinu multipl phase ib/iia trial preliminari data first cohort lowest dose studi shown
phase ib/iia waiha studi igg reduct dose weekli week
phase ib/iia pemphigu vulgari pv /foliaceu pf studi igg reduct dose weekli week
phase healthi volunt studi igg reduct dose weekli week
result phase
ib/iia studi moder
sever pv/pf
administ top
soc corticosteroid
syntimmun alexion pharmaceut compani present press releas
kol insight futur waiha treatment landscap
steroid still prefer first-lin therapi kol note
patient long-term respons literatur suggest
patient usual taper steroid within month given
associ ae profil prescrib rituximab second-lin agent
patient respond rituximab major
tend relaps within first two year therapi well
kol gener excit prospect fostamatinib given
respons rate waiha oral rout administr manag side
effect profil vs steroid rituximab
kol mix waiha applic
patient patient pop limit clinic data
administ via subcutan infus
kol believ mechanist rational behind fcrn inhibit solid
readthrough itp data want see clinic
data determin use waiha treatment landscap
treatment algorithm base kol feedback shown next slide
would guess feedback mechan reset
immun system significantli reduc igg level
autoantibodi caus diseas probabl wont
rebound quickli normal antibodi predict
see patient come one
fcrn inhibitor mention long term remiss
data fcrn class respons itp
may serv proof principl use fostamatinib
refer drug approv itp base
sustain respons rate phase ii studi waiha
show respons rate earli guess respons
rate fcrn class think work
kol believ novel pipelin therapi address larg unmet need waiha diseas highli refractori current
treatment earli kol believ fcrn inhibitor clinic potenti base mechan respons itp
futur waiha treatment algorithm base kol feedback
commonli use
necessari sever patient
relaps rate
phase ii favor oral roa
applic
kol note fostamatinib fcrn inhibitor potenti move
first line set provid respons rate similar glucocorticoid rituximab
favor patient
kol note earli differenti pipelin therapi set given lack clinic data base avail
respons relaps rate howev kol believ patient treat multipl novel therapi cours diseas
waiha market assumpt lead non-risk adjust sale
diseas preval autoimmun hemolyt anemia rare diseas incid preval per individu
respect waiha common form diseas account case base epidemiolog data well
estim immunov rigel pharma momenta estim case waiha us
diseas growth rate assum diseas growth rate line us popul
role waiha treatment paradigm discuss previou slide earli differenti pipelin
therapi second third-lin set given lack clinic data pipelin therapi potenti
move treatment paradigm model primarili use set corticosteroid rituximab order
conserv howev may incorpor use earlier treatment line data anti-fcrn class becom avail
remind patient achiev long-term remiss steroid first line set incorpor relaps rate
patient relaps rituximab second line set well use median model
penetr rate kol gener excit fostamatinib waiha advanc clinic develop oral
rout administr compar sc fcrn inhibitor iv therefor believ asset captur good
portion market even respons rate high fcrn inhibitor given lack clinic data current
assum three fcrn inhibitor develop waiha equal captur market although like chang
addit data overal estim take year reach peak penetr us
price sinc waiha rare diseas high unmet need expect price annual net-cost
model assum net price increas line us inflat rate
continu slide
waiha market assumpt lead non-risk adjust sale
market entri model assum market entri us assumpt behind follow
top-line phase ii top-line result waiha
end phase top-line result waiha base expect time frame
conduct phase trial rigel fostamatinib
early-mid file nda waiha
end potenti approv launch waiha model earli
complianc sinc weekli subcutan inject like taken chronic basi assign complianc rate
order account potenti miss dose
probabl success seen clinic data fcrn inhibitor waiha kol believ clinic potenti
given mechan respons itp therefor current assign probabl success stage develop although
number like shift base futur clinic data
net us/row sale assumpt lead non-risk-adjust risk-adjust us sale year end march
respect also model rest world sale base comp weve found hematolog space global non-risk adjust
risk-adjust sale year end march respect
patient popul growth patient requir steroid relaps patient requir rituximab relaps patient treat penetr rate- annual net chang price- compliance- us sale probabl success- probabl adjust sale rest world probabl adjust sale probabl adjust sale januari
larg academ institut
author medic
articl thrombot
involv multipl on-going
patient underli diseas associ waiha treatment algorithm
differ secondari waiha patient tend increas risk thrombot event
steroid effect therapi patient long term remiss given
associ patient usual taper steroid within mo prescrib rituximab
least patient respond rituximab relaps within first two year
kol believ larg unmet need waiha
kol excit phase ii data fostamatinib hemoglobin respons side effect
limit also note asset oral roa meaning advantag patient need come
kol note fostamatinib inhibit phagocytosi antibody-co cell prevent
complement activ potenti asset block higher respons rate
kol less excit waiha applic patient
patient pop limit clinic data believ therapi applic
caiha complement activ play larger role diseas
clinic data present fcrn inhibitor kol believ class
efficaci cite readthrough itp studi note imposs differenti
fcrn inhibitor without see data one know level igg reduct need reach
kol note patient relaps steroid rituximab pipelin asset like use
patient receiv multipl novel asset effect
hematologist larg academ
uk institut consult
nh author aiha
multipl waiha trial
steroid still prefer therapi respond initi remain remiss
guidelin mention combin rituximab steroid base clinic efficaci shown
small studi commonli use physician
kol note rituximab therapi choic respons initi major
patient relaps well given invas natur splenectomi longer popular among patient
kol excit fostamatinib respons rate trial particip refractori multipl therapi
note ae profil manag note oral roa would prefer patient
hand kol mix sinc applic subset patient
popul administ via sc infus sinc inhibit complement activ note
would probabl use therapi sever patient limit thrombot risk
kol believ fcrn inhibitor work mechanist perspect note
imposs determin expect respons rate without clinic data
note posit data itp may posit readthrough exampl fostamatinib
respons rate itp respons rate phase ii studi waiha
kol believ albumin decreas headach limit fcrn inhibitor use clinic
concern infect potenti long term igg reduct note hasnt seen yet
kol note prescript choic come respons rate vs rituximab given
relaps rate howev kol note patient receiv multipl therapi cours diseas
part agreement hanal biopharma immunov exclus license patent famili next-
gener antibodi us canada mexico eu uk switzerland middl east north africa latin america
patent applic also pend us argentina brazil canada europ patent offic egypt israel mexico saudi arabia
patent concern composit matter method use project expir april us
jurisdict subject termin disclaim patent term extens list region key patent includ follow
us patent issu juli claim concern pharmaceut composit compris isol fcrn antibodi
antigen-bind fragment notic allow claim direct pharmaceut composit antibodi method
treat variou autoimmun diseas use antibodi method produc antibodi receiv sep
addit immunov file provision patent applic us regard method treat autoimmun diseas imvt-
jan may accept patent famili would expir jan may respect
model valuat
dcf sensit analysi
imvt dcf sensit price per share discount dcf summarysum fcfe forma equiti close share outstand discount termin growth includ dilut earnout stock price reach per share januari
profit loss
imvt except per share fy adjust revenue/oth -- -- -- -- -- -- -total prob adj product sale royalti hanall- royalti hanall- mileston payment hanall- cog product sales- product oper incom schedul incom outstand lifesci capit estim compani report januari
imvt year end march oper activitiesnet incom base compens currenc translat dispos properti oper asset cash provid use oper properti cash use invest parent proce issuanc common defer ipo cash provid financ increas decreas cash equival restrict cash equival begin cash equival lifesci capit estim compani report januari
lifesci capit lsc research analyst denot ac cover report certifi multipl research analyst primarili
respons report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur reflect
person view subject secur subject compani part research analyst compens
directli indirectli relat specif recommend view express research analyst report
